ACE and heart failure: In patients with heart failure with a reduced left ventricular ejection fraction (HFrEF), sacubitril/valsartan has been demonstrated to be superior to ACE inhibitors (ACEi) in decreasing the risk of heart failure hospitalization and death [1], and in reversing left ventricular remodeling [2,3].